Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Society Webinar Archive – The Future of CAR-T Therapy: Can CAR-T Cure CLL?

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

CLL Society Webinar Archive – The Future of CAR-T Therapy: Can CAR-T Cure CLL?

Recorded November 17, 2020.
 

Welcome:

Patty Koffman
Co-founder and Communications Director
CLL Society

Moderator:

Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd
Executive Vice President and Chief Medical Officer
CLL Society

Speaker:

Joseph A. Fraietta, PhD
Assistant Professor of Microbiology
Perelman School of Medicine
Philadelphia, PA

Dr. Fraietta has developed novel approaches for the treatment of cancer through genetic modification of T lymphocytes that contributed to the initiation of multiple clinical trials and FDA approval of the first CAR T cell therapy. In 2015, Dr. Fraietta assumed the directorship of a research laboratory in the first-of-its-kind Center for Advanced Cellular Therapies where his group led initiatives to use CAR-T cell infusion products for key biomarkers and mechanisms of potency, with the objective of predicting clinical responses to adoptive cell therapies. He now directs the Tumor Immunotherapy Laboratory as a faculty member in the same center.

Description:

CAR-T is a revolutionary therapy in CLL and other blood cancers. As part of the team led by Dr. Carl June at U. Penn, Dr. Joe Fraietta’s translational research has taken CAR-T from an exciting possibility to a lifesaving “living drug”. Don’t miss this opportunity to be able to learn about the latest CAR-T research and to ask your questions of one of CAR-T’s most innovative pioneers.

This program was made possible by the support of Adaptive Biotechnologies, Bristol Meyers Squibb, Genentech, and Novartis.